What Is Elamipretide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Elamipretide is FDA-approved only as Forzinity for a specific Barth syndrome indication. Products sold online as elamipretide, SS-31, MTP-131, Bendavia, mitochondrial peptide, research-use elamipretide, or “mitochondrial optimization” peptide may carry safety, quality, legal, and regulatory risks.

Quick answer

Elamipretide is a mitochondria-targeted peptide and cardiolipin binder. It is also known as SS-31, MTP-131, and Bendavia. In September 2025, the FDA granted accelerated approval to Forzinity, elamipretide injection, as the first treatment for Barth syndrome in adult and pediatric patients weighing at least 30 kg. The approved indication is to improve muscle strength, and approval is based on improvement in knee extensor muscle strength, an intermediate clinical endpoint. Continued approval may depend on confirmatory clinical benefit data. Elamipretide is not approved for anti-aging, general mitochondrial optimization, athletic recovery, chronic fatigue, dry AMD, primary mitochondrial myopathy, or general wellness use.

Key facts about Elamipretide

What is Elamipretide?

Elamipretide is a mitochondria-targeted peptide that binds cardiolipin. Cardiolipin is a specialized phospholipid found in the inner mitochondrial membrane. It is important for mitochondrial membrane structure and normal electron transport chain function.

Elamipretide has been studied under several names:

• Elamipretide
• Forzinity
• SS-31
• MTP-131
• Bendavia
• Elamipretide hydrochloride

The FDA describes Forzinity as working by binding to the inner part of the mitochondria and improving mitochondrial structure and function. The FDA granted accelerated approval to Forzinity as the first treatment for Barth syndrome in patients weighing at least 30 kg.

The key distinction:

Elamipretide is now an FDA-approved drug for a specific rare mitochondrial disease indication, not a general-purpose mitochondrial supplement or anti-aging peptide.

How does Elamipretide work?

Elamipretide targets mitochondria, specifically the inner mitochondrial membrane.

Its main proposed mechanism is binding to cardiolipin, a phospholipid that helps organize mitochondrial membrane structure and supports normal energy production.

Research and company materials describe elamipretide as having effects on:

• Mitochondrial cardiolipin binding
• Inner mitochondrial membrane structure
• Mitochondrial respiration
• Electron transport chain function
• ATP production
• Reactive oxygen species regulation
• Mitochondrial bioenergetics
• Barth syndrome-related mitochondrial dysfunction

In plain English:

Elamipretide is designed to help damaged or dysfunctional mitochondria work more normally by stabilizing part of the inner mitochondrial membrane.

That is very different from ordinary “mitochondrial support” supplements.

But mechanism is not universal proof.

A mitochondrial mechanism does not prove that elamipretide treats normal aging, improves athletic performance, reverses fatigue, fixes all mitochondrial dysfunction, prevents disease, or works as a general longevity peptide.

What is Elamipretide used for?

Elamipretide is approved for one narrow Barth syndrome indication and is investigational for other uses.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Barth syndrome muscle strength | FDA accelerated approval | Forzinity is approved to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg. | Continued approval may depend on confirmatory clinical benefit data. | | Barth syndrome symptoms and function | Moderate clinical evidence | TAZPOWER and extension data reported functional and symptom improvements in Barth syndrome studies. | Evidence comes from ultra-rare disease trials with small sample sizes. | | Primary mitochondrial myopathy | Investigational | Elamipretide has been studied in mitochondrial myopathy programs. | It is not FDA-approved for primary mitochondrial myopathy. | | Dry age-related macular degeneration | Investigational | Stealth lists late-stage ophthalmic studies in dry AMD. | It is not FDA-approved for dry AMD. | | General mitochondrial dysfunction | Mechanistic / investigational | Mitochondrial targeting and cardiolipin biology are plausible. | Broad mitochondrial disease benefit is not established. | | Chronic fatigue / low energy | Unsupported as a consumer claim | Mitochondrial dysfunction can affect fatigue in disease contexts. | Elamipretide is not approved for fatigue or low energy. | | Anti-aging / longevity | Unsupported | Mitochondria are involved in aging biology. | No strong evidence supports elamipretide as an anti-aging therapy. | | Athletic recovery / performance | Unsupported | ATP and mitochondrial claims attract performance marketing. | It is not approved or proven for performance enhancement. | | Online research-use elamipretide | High risk | Sellers may market mitochondrial peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |

What does the research show?

FDA approval for Barth syndrome

The most important current fact is FDA approval.

The FDA granted accelerated approval to Forzinity, elamipretide injection, as the first treatment for Barth syndrome in patients weighing at least 30 kg. The FDA says approval is based on improvement in knee extensor muscle strength, an intermediate clinical endpoint considered reasonably likely to predict patient benefit. As a condition of accelerated approval, the manufacturer must conduct a randomized, double-blind, placebo-controlled confirmatory trial.

The DailyMed prescribing information states that Forzinity is a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. It also states that continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial.

The practical interpretation:

Elamipretide is no longer simply investigational in the U.S., but its approval is narrow and conditional.

Barth syndrome clinical evidence

A PubMed-indexed phase 2/3 randomized clinical trial followed by an open-label extension evaluated elamipretide in Barth syndrome. The randomized portion did not meet its primary endpoints, but open-label extension results showed improvements in 6-minute walk test, Barth Syndrome Symptom Assessment, knee extensor strength, patient global impression of symptoms, and some cardiac parameters.

A later PubMed-indexed 168-week open-label extension reported sustained long-term tolerability and efficacy signals, including functional and cardiac-function improvements in Barth syndrome.

The practical interpretation:

The Barth syndrome evidence is meaningful for a severe ultra-rare disease, but the clinical dataset is small and the approval requires confirmatory evidence.

Mitochondrial mechanism evidence

Stealth BioTherapeutics describes elamipretide as a peptide that penetrates cell membranes and targets the inner mitochondrial membrane, where it binds reversibly to cardiolipin. The company states that elamipretide has been observed in preclinical or clinical studies to increase mitochondrial respiration, improve electron transport chain function and ATP production, reduce pathogenic reactive oxygen species, and normalize inner mitochondrial membrane structure.

A PMC review on Barth syndrome cardiomyopathy discusses elamipretide as a therapeutic approach that crosses the mitochondrial outer membrane, localizes to the inner membrane, and associates with cardiolipin.

The practical interpretation:

Elamipretide’s mitochondrial mechanism is serious and disease-relevant, especially in Barth syndrome, but it should not be stretched into general wellness claims.

Primary mitochondrial myopathy and dry AMD

Stealth BioTherapeutics lists elamipretide clinical development in late-stage studies for ophthalmic diseases involving mitochondrial dysfunction, including dry age-related macular degeneration, and rare neuromuscular disorders such as primary mitochondrial myopathy.

That does not mean those uses are approved.

The practical interpretation:

Elamipretide remains investigational for dry AMD, primary mitochondrial myopathy, and other mitochondrial-dysfunction indications.

Evidence summary

Is Elamipretide FDA-approved?

Yes, but only for a specific use.

Forzinity, elamipretide injection, is FDA-approved under accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

This does not mean elamipretide is approved for:

• Anti-aging
• Longevity
• General mitochondrial support
• Chronic fatigue
• Athletic recovery
• Healthy-person energy enhancement
• Primary mitochondrial myopathy
• Dry age-related macular degeneration
• Parkinson’s disease
• Heart failure
• General cardiomyopathy
• General wellness use

The key distinction:

Forzinity approval is real, but narrow. Elamipretide is not a general mitochondrial optimization drug.

Is Elamipretide legal?

Elamipretide’s legal status depends on product type, jurisdiction, prescription status, and intended use.

A legitimate Forzinity prescription for the approved Barth syndrome indication is different from an online “research use only” elamipretide product.

The practical answer for U.S. readers:

Elamipretide is FDA-approved only as Forzinity for a specific Barth syndrome indication. Online elamipretide sold as a research peptide is not the same as an FDA-approved prescription product.

The blunt version:

Buying “research use only” elamipretide online is not the same as receiving Forzinity through a legitimate prescription channel.

Is Elamipretide banned in sports?

I did not find elamipretide specifically named on the WADA prohibited list in the sources reviewed here.

However, athletes should be careful for several reasons:

1. It is a pharmacologic peptide.
2. Anti-doping status can change.
3. Clinical-trial or prescription drugs can still create anti-doping questions.
4. Online research-use peptide products may be contaminated or mislabeled.
5. WADA and USADA advise athletes to verify medication status through official anti-doping resources.

The practical advice:

Athletes should verify elamipretide or Forzinity through Global DRO, WADA, or USADA before use and should avoid unapproved online peptide products.

Safety and side effects

Elamipretide has real pharmacologic activity. It should not be treated like a harmless mitochondrial supplement.

For the FDA-approved Forzinity product, the FDA states that the most common side effects identified in clinical trials were mild-to-moderate injection-site reactions. DailyMed lists injection-site reactions including erythema, pain, induration, pruritus, bruising, and urticaria.

Possible or reported concerns include:

• Injection-site redness
• Injection-site pain
• Injection-site itching
• Injection-site bruising
• Injection-site swelling or induration
• Injection-site urticaria
• Hypersensitivity reactions
• Serious allergic reactions
• Unknown long-term effects outside studied populations
• Limited evidence in very small rare-disease trial populations
• Product-quality and sterility risks from online sources
• Mislabeling or incorrect concentration in research-use products

A serious evaluation of elamipretide should separate:

Elamipretide vs similar peptides and drugs

The key distinction:

Elamipretide belongs in the mitochondrial cardiolipin-binding peptide category. It is not a GLP-1 drug, growth hormone peptide, cosmetic peptide, repair peptide, or generic supplement.

Why is Elamipretide sold as “research use only”?

Some online sellers may use “research use only” language to sell elamipretide or SS-31 outside normal prescription channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate Elamipretide claims online

Bottom line

Elamipretide is a mitochondria-targeted cardiolipin-binding peptide. It is now FDA-approved under accelerated approval as Forzinity to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. That is a major milestone because it is the first FDA-approved treatment for Barth syndrome.

The most defensible conclusion is:

Elamipretide is a legitimate mitochondrial disease drug with a narrow FDA-approved indication, not a general anti-aging or mitochondrial optimization peptide. Broader claims for fatigue, longevity, athletic recovery, primary mitochondrial myopathy, dry AMD, and general mitochondrial dysfunction remain unapproved or investigational. Readers should distinguish Forzinity from unapproved online SS-31 or elamipretide products with uncertain identity, purity, sterility, concentration, and legality.

FAQ

What is Elamipretide?

Elamipretide is a mitochondria-targeted peptide that binds cardiolipin in the inner mitochondrial membrane. It is also known as SS-31, MTP-131, and Bendavia.

What is Forzinity?

Forzinity is the FDA-approved brand name for elamipretide injection.

Is Elamipretide FDA-approved?

Yes, but only for a narrow indication. Forzinity is FDA-approved under accelerated approval to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg.

What is Barth syndrome?

Barth syndrome is a rare, serious, life-threatening mitochondrial disease that primarily affects males and can cause heart failure, fatigue, poor stamina, exercise intolerance, muscle weakness, recurrent infections, and reduced life expectancy.

How does Elamipretide work?

Elamipretide targets the inner mitochondrial membrane and binds cardiolipin, which may improve mitochondrial structure, respiration, electron transport chain function, ATP production, and oxidative-stress handling in studied disease contexts.

Is Elamipretide approved for anti-aging?

No. Elamipretide is not approved for anti-aging, longevity, general mitochondrial support, or wellness use.

Is Elamipretide approved for primary mitochondrial myopathy?

No. Elamipretide has been studied for primary mitochondrial myopathy, but it is not FDA-approved for that indication.

Is Elamipretide approved for dry AMD?

No. Elamipretide is being studied in dry age-related macular degeneration, but it is not FDA-approved for dry AMD.

Is Elamipretide the same as SS-31?

Yes, SS-31 is a research name commonly used for elamipretide. Forzinity is the FDA-approved prescription product name for the approved Barth syndrome indication.

Is Elamipretide safe?

Elamipretide has FDA-reviewed safety data for the approved Forzinity indication, but it is not risk-free. Common adverse reactions include injection-site reactions such as redness, pain, induration, itching, bruising, and urticaria. Serious hypersensitivity reactions can occur.

Is Elamipretide legal in the U.S.?

Forzinity is FDA-approved for a specific Barth syndrome indication. Online elamipretide or SS-31 sold as a research peptide is not the same as an FDA-approved prescription product.

Is Elamipretide banned in sports?

I did not find elamipretide specifically named on the WADA prohibited list in the sources reviewed here. Athletes should verify current status with WADA, USADA, or Global DRO before use.

Why do sellers call Elamipretide “research use only”?

Sellers often use “research use only” language because their elamipretide products are not FDA-approved prescription Forzinity. The phrase does not make the product safe, legal, approved, or equivalent to the regulated drug.

What is the biggest risk with Elamipretide?

The biggest risks are confusing the narrow FDA-approved Forzinity indication with broad mitochondrial wellness claims, using unapproved online products with uncertain quality, and assuming mitochondrial targeting proves anti-aging, fatigue, or performance benefits.

Sources

1. FDA: FDA Grants Accelerated Approval to First Treatment for Barth Syndrome
2. DailyMed: Forzinity, elamipretide hydrochloride injection
3. FDA Prescribing Information PDF: Forzinity label
4. FDA Integrated Review: Elamipretide
5. Stealth BioTherapeutics: Elamipretide Clinical Trials and Pipeline
6. PubMed: Phase 2/3 randomized clinical trial followed by open-label extension in Barth syndrome
7. PMC: Phase 2/3 randomized clinical trial followed by open-label extension in Barth syndrome
8. PubMed: 168-week open-label extension results of TAZPOWER
9. PubMed: Elamipretide in the Management of Barth Syndrome
10. PMC: Barth syndrome cardiomyopathy, targeting the mitochondria with elamipretide
11. PMC: Expanded-access use of elamipretide in a critically ill patient with Barth syndrome
12. PubMed: Elamipretide for Barth syndrome cardiomyopathy
13. WADA: Prohibited List
14. USADA: WADA Prohibited List Guidance